---
source_pdf: "https://drive.google.com/file/d/1wiVeGtUw6BlNT6goiF4Wc9FsSqistGtGwLGNt6qoIKI/view"
drive_folder: "Portfolio/Tuva Health/Tuva Health/Tuva-Data-Room"
type: portfolio
company: Tuva Health
ingested: 2025-12-27
original_filename: "Tuva Feature Comp"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/1wiVeGtUw6BlNT6goiF4Wc9FsSqistGtGwLGNt6qoIKI/view)

## Slide 1: Tuva Slides

Tuva Slides

## Slide 2: Our platform comprises multiple features that are doing $XB+ in revenue

Our platform comprises multiple features that are doing $XB+ in revenue

| Feature                 | Example Company / ARR                                                                   |
| :---------------------- | :-------------------------------------------------------------------------------------- |
| Enterprise Core Platform | Innovaccer, Arcadia, Abacus, Health Catalyst, Milliman MedInsight                     |
| Real-time clinical data | Zus, Particle, Health Gorilla, Metriport, Kno2, xCures                                  |
| Data normalization      | IMO, John Snow Labs, Layer Health, Emtelligent, ScienceIO                               |
| EMPI                    | Verato, Rhapsody, MultiVue, Profisee                                                    |
| NCQA Hedis Measures     | Inovalon, Cotiviti                                                                      |
| Clinical Episode        | Optum ETG, Solventum (3M) CRG, Johns Hopkins ACG System, Merative MEG                   |
| Risk Models             | Milliman, Optum, Verisk, Solventum                                                      |
| Benchmarking            | Merative, Clarify, Trilliant                                                            |
| Data Monetization       | Truveta, Datavant, Komodo, Purple Lab                                                   |

## Slide 3: Sources

Sources

*   Innovaccer - $250M ARR; investment deck from 2021
*   IMO - $60M in EBITDA in 2022 -> ~$200M+ revenue today given typical EBITDA margins
*   Inovalon (investor deck)
*   Cotiviti (investor deck)
*   Solventum (investor deck)
*   Datavant - $300M in EBITDA (Ciox majority; 15-20% EBITDA margins)
*   Trilliant - $30-$60M
*   Komodo -
*   Purple Lab -

## Slide 4: Comparison Table

|           | Milliman                                                               | Wakely                                                                                               | Axene                                                                                                                  | Arbital                                                                                                   | Accorded                                                                      |
| :-------- | :--------------------------------------------------------------------- | :--------------------------------------------------------------------------------------------------- | :--------------------------------------------------------------------------------------------------------------------- | :-------------------------------------------------------------------------------------------------------- | :---------------------------------------------------------------------------- |
|           | Independent consulting firm specializing in healthcare, insurance and financial services | Actuarial and healthcare consulting firm specializing in healthcare analytics and actuarial services | Healthcare consulting firm specializing in actuarial and clinical consulting and financial / operational analytics | Healthcare technology company building a third-party adjudication utility to support VBC contracts      | Technology-powered actuarial insights and analytics to make healthcare contracting efficient and scalable |
|           | 4,800 employees, 60+ offices                                           | 80+ actuarial experts and consultants, 6 officers                                                    | 11-50 employees                                                                                                        | $26M valuation                                                                                            | 11-50 employees                                                               |
|           | Actuarial, healthcare, life, P&C, and benefits consulting              | Healthcare, actuarial ACA, MA, Risk adjustment consulting, data analysis and modeling                | Clinical and VBC consulting, healthcare strategy, medical director services                                            | Platform includes data ingestion, performance monitor, adjudication, predictive outreach, reconciliation | SaaS platform                                                                 |
|           | N/A                                                                    | N/A                                                                                                  | N/A                                                                                                                    | N/A                                                                                                       | N/A                                                                           |
|           | Dermot Corry - CEO                                                     | Tim Courtney- CEO                                                                                    | David Axene - Founder & President                                                                                      | Brian Overstreet - CEO                                                                                    | Frank Cheung, CEO                                                             |
|           | Employee-owned, federated model                                        | Private, acquired by Health Management Associates, Inc. (2021)                                       | Management                                                                                                             | Transformation, Flex Capital, Healthy Ventures, Shaper Capital, Underdog Labs                           | Fika Ventures, Susa Ventures, Stepstone                                       |
|           | **~$1.5B**                                                             | **~$70M**                                                                                            | **~$15M**                                                                                                              | **Unknown**                                                                                               | **$3.5M**                                                                     |

## Slide 5: Our domain specificity allows us to own more of the data stack (Fivetran + dbt + BI)

Our domain specificity allows us to own more of the data stack (Fivetran + dbt + BI)

## Slide 6: Why is this advantageous for customers?

Why is this advantageous for customers?